Key factors
sym | NK |
exch | US |
MCap | 3.552B |
Beta | 2.386 |
EPS | -0.89 |
Div date | 0000-00-00 |
Yesterday
sym | NK |
exch | US |
50 Day MA | 28.70 |
200 Day MA | 14.18 |
52 Week High | 46.82 |
52 Week Low | 11.82 |
Target Price | 18.0 |
Market Cap Mln | 3552.62 |
Share statistics
Shares Outstanding | 109.34M |
Shares Float | 41.15M |
Percent Institutions | 9.779 |
PercentInsiders | 67.97 |
SharesShort | 3914.89K |
Short Ratio | 3.71 |
Shares Short Prior Month | 5432.94K |
Short Percent | 15.46 |
Income
Revenue TTM | 111.0K |
Revenue Per Share TTM | 0.001 |
Quarterly Revenue Growth YOY | 133.29 |
Gross Profit TTM | 111.0K |
EBITDA | -65.2M |
Diluted Eps TTM | -0.89 |
earning
Operating Margin TTM | -769.6 |
PEGRatio | 2.56 |
EPS Estimate Current Quarter | -0.18 |
EPS Estimate Current Year | -0.84 |
EPS Estimate Next Year | -0.97 |
Earnings Share | -0.89 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 2012-08-17 |
Last Split Factor | 8:1 |
business
Enterprise Value Revenue | 31559 |
Book Value /share | 1.08 |
Price Book MRQ | 30.26 |
Price Sales TTM | 30309 |
ReturnOnAssetsTTM | -0.36 |
ReturnOnEquityTTM | -0.77 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US45256X1037 |
CIK | 1326110 |
Code | NK |
CUSIP | 63016Q102 |
Employer Id Number | 43-1979754 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2021-12-05 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 171.0 |
IPODate | 2015-07-28 |
International Domestic | Domestic |
MostRecent Quarter | 2020-12-31 |
Contact
Name | NantKwest Inc |
Address | 3530 John Hopkins Court, San Diego, CA, United States, 92121 |
Country Name | USA |
Phone | 858 633 0300 |
Web URL | www.nantkwest.com |
Logo URL | /img/logos/US/NK.png |
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.